We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
Read MoreHide Full Article
Viking Therapeutics, Inc. (VKTX - Free Report) ended the recent trading session at $64.11, demonstrating a -0.9% swing from the preceding day's closing price. This change lagged the S&P 500's 0.17% loss on the day. Meanwhile, the Dow lost 0.44%, and the Nasdaq, a tech-heavy index, lost 0.04%.
Coming into today, shares of the company had gained 11.34% in the past month. In that same time, the Medical sector lost 3.8%, while the S&P 500 gained 1.25%.
The investment community will be closely monitoring the performance of Viking Therapeutics, Inc. in its forthcoming earnings report. The company is forecasted to report an EPS of -$0.24, showcasing a 4.35% downward movement from the corresponding quarter of the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Viking Therapeutics, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 0.99% fall in the Zacks Consensus EPS estimate. Viking Therapeutics, Inc. currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 75, positioning it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VKTX in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
Viking Therapeutics, Inc. (VKTX - Free Report) ended the recent trading session at $64.11, demonstrating a -0.9% swing from the preceding day's closing price. This change lagged the S&P 500's 0.17% loss on the day. Meanwhile, the Dow lost 0.44%, and the Nasdaq, a tech-heavy index, lost 0.04%.
Coming into today, shares of the company had gained 11.34% in the past month. In that same time, the Medical sector lost 3.8%, while the S&P 500 gained 1.25%.
The investment community will be closely monitoring the performance of Viking Therapeutics, Inc. in its forthcoming earnings report. The company is forecasted to report an EPS of -$0.24, showcasing a 4.35% downward movement from the corresponding quarter of the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Viking Therapeutics, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 0.99% fall in the Zacks Consensus EPS estimate. Viking Therapeutics, Inc. currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 75, positioning it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VKTX in the coming trading sessions, be sure to utilize Zacks.com.